CRP and inflammatory bowel disease: Guidelines on the treatment of IBD endeavor to induce and maintain endoscopic remission, achieve steroid-free remission, and decrease the number of hospitalizations and surgeries.2 The recent STRIDE II guidelines focus on a treat-to-target model to obtain a clinical response and remission, the normalization of inflammatory markers (C-reactive protein [CRP] and fecal calprotectin), and endoscopic healing.3